Dynavax's Heplisav-B outperforms GSK shot in PhIII trial


Dynavax is touting Phase III data announced this week showing that its hepatitis B vaccine Heplisav-B bested the standard-of-care Engerix-B, marketed by GlaxoSmithKline ($GSK) and first approved in 1989.

Berkeley, CA-based Dynavax said its candidate demonstrated statistically significant higher seroprotection rates of 95% compared to 81% for the Engerix-B group. For the trial, dubbed HBV-23, investigators divided participants into an 18-to-39 age range, finding that 99% of people in that group who received Heplisav-B were seroprotected versus 93% in the Engerix-B arm. The other group, ages 40 to 70, showed seroprotection rates of 95% for Heplisav-B compared to 79% for Engerix-B.

Dynavax’s vaccine is administered in two doses one month apart versus Engerix-B’s regimen of three doses over 6 months, a fact that RBC Capital Market’s Simos Simeonidis has previously said could help the shot get a majority of a $270 million market upon approval.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Bell’s palsy occurred in 0.09% of the Heplisav-B participants in the HBV-23 trial versus a rate of 0.04% in the Engerix-B group. Investigators noted single cases each of alopecia areata, polymyalgia rheumatic and ulcerative colitis in the Heplisav-B arms, as well. The data bring the vaccine’s safety database to 14,238 participants, more than 10,000 of whom have received Heplisav-B.

The PDUFA date for Heplisav-B is Sept. 15, 2016.

- here’s the release

Related Article:
Analyst: Dynavax hep B vaccine positioned to grab market share from GSK's Engerix-B

Suggested Articles

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.